Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wataru Okamoto

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|August 7, 2010
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsIsamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, et al.
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Targeted Oncology|May 7, 2022
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care ChemotherapyTakuro Mizukami, Masaki Takahashi, Yu Sunakawa, et al.
Breast Cancer (Tokyo, Japan)|November 30, 2011
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610BHidetoshi Hayashi, Junji Tsurutani, Taro Satoh, et al.
Scientific Reports|June 14, 2023
Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogsWataru Okamoto, Tomone Usui, Mai Hasegawa, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 27, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibYasutoshi Fujii, Atsushi Ono, C Nelson Hayes, et al.
BMJ Open|October 5, 2023
Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective studyKo Oshita, Tsuyoshi Kobayashi, Yosuke Namba, et al.
Clinical Journal of Gastroenterology|November 17, 2020
A case with life-threatening secondary sclerosing cholangitis caused by nivolumabYuki Yoshikawa, Michio Imamura, Kenji Yamaoka, et al.
JCO Precision Oncology|January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH TrialMitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
Future Oncology (London, England)|May 5, 2022
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trialAkihiro Ohba, Chigusa Morizane, Makoto Ueno, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|August 7, 2010
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsIsamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, et al.
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Targeted Oncology|May 7, 2022
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care ChemotherapyTakuro Mizukami, Masaki Takahashi, Yu Sunakawa, et al.
Breast Cancer (Tokyo, Japan)|November 30, 2011
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610BHidetoshi Hayashi, Junji Tsurutani, Taro Satoh, et al.
Scientific Reports|June 14, 2023
Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogsWataru Okamoto, Tomone Usui, Mai Hasegawa, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 27, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibYasutoshi Fujii, Atsushi Ono, C Nelson Hayes, et al.
BMJ Open|October 5, 2023
Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective studyKo Oshita, Tsuyoshi Kobayashi, Yosuke Namba, et al.
Clinical Journal of Gastroenterology|November 17, 2020
A case with life-threatening secondary sclerosing cholangitis caused by nivolumabYuki Yoshikawa, Michio Imamura, Kenji Yamaoka, et al.
JCO Precision Oncology|January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH TrialMitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
Future Oncology (London, England)|May 5, 2022
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trialAkihiro Ohba, Chigusa Morizane, Makoto Ueno, et al.
Pageof 10